Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Refractec
AddedMar 20, 2024
UpdatedJun 18, 2026
Refractec

Refractec

Innovative ophthalmic device for near vision improvement.

HQ
Bloomington, MN, US
Founded
1993
Overview
Compare
Fundraising
Employees

Refractec is an ophthalmic medical device company that develops and markets an innovative and proprietary radiofrequency (RF) device called the ViewPoint® CK System. The ViewPoint CK System, used to perform the NearVisionSM CK® (Conductive Keratoplasty®) treatment, is the only FDA-approved technology that temporarily improves near vision for the 37 million presbyopic emmetropes and presbyopic hyperopes in the USA, and can be conveniently performed in-office in just a few minutes.

NearVision CK was ranked the #1 non-laser refractive procedure in the USA, according to Market Scope's 2005 Annual Survey of Cataract and Refractive Surgeons, and is an effective, safe and minimally-invasive alternative for the millions of conservative, plano presbyopic baby boomer patients who may be apprehensive about laser vision correction surgery, and are seeking to reduce their dependence on reading glasses and improve their near vision

Refractec - Similar Companies

ReVision Optics logo

ReVision Optics

revisionoptics.com

ReaLens logo

ReaLens

RxSight logo

RxSight

rxsight.com

Clerio Vision logo

Clerio Vision

cleriovision.com

Vision Care Connect logo

Vision Care Connect

Teclens logo

Teclens

teclens.com

Neuroptics logo

Neuroptics

neuroptics.com

Retina Technologies logo

Retina Technologies

MicroOptx logo

MicroOptx

Zepto logo

Zepto

PercuVision logo

PercuVision

EyeNetra logo

EyeNetra

eyenetra.com

Visiontech CDI Forus logo

Visiontech CDI Forus

vtivision.com

Glaukos logo

Glaukos

glaukos.com

eyeThera logo

eyeThera

eyethera.com

Refractec - Quick Facts

Who are Refractec's competitors?

Companies similar to Refractec include ReVision Optics, ReaLens, RxSight and Clerio Vision.

When was Refractec founded?

Refractec was founded in 1993.

Where is Refractec's headquarters located?

Refractec's headquarters is located in Bloomington, MN, US.

When was Refractec's last funding round?

Refractec's most recent funding round was for $9M (USD) in July 2003.

How much has Refractec raised to-date?

As of Jul 18, 2003, Refractec has raised a total of $14M (USD).

How many employees does Refractec have?

Refractec has 5 employees as of Feb 4, 2024.

Refractec - Classification

Industry
  • Hardware
Ownership
  • Private
  • Venture Capital
Technology
  • RFID
Geographic Exposure
  • Americas
Revenue
  • Recurring
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified